Development Route
Launch of the Precious Fungi Restoration Initiative
By integrating an elite Cordyceps sinensis research team from the Tibetan Plateau, we are committed to the traditional cultivation methods of Cordyceps. Furthermore, we have synthesized the expertise of Taiwan's leading biotechnology research teams to pioneer new cultivation technologies for Taiwanofungus Camphoratus, effectively implementing our Precious Fungi Restoration Initiative.
Inauguration of the Cordyceps Sinensis Restoration & Cultivation Base
A Cordyceps Sinensis Cultivation Center has been established in Chengdu, China, marking the formal commencement of our restoration efforts. We have pioneered proprietary technologies, including 'Targeted Cultivation' and 'Pathological Section-Based Infection Methods,' significantly enhancing the infection rates of ghost moth larvae.
Official Establishment of Cordyceps Sunshine Biotech Holdings Co., Ltd.
Branch offices were established in Hong Kong and Taiwan to oversee regional operations.
Successfully secured patents for Taiwanofungus Camphoratus cultivation technology and obtained multiple laboratory testing and appraisal reports
Our proprietary 'Method for Cultivating Taiwanofungus Camphoratus and Porous Carrier for the Same' has been granted patents in both Taiwan and China. Furthermore, our products have successfully passed rigorous evaluations by the Evolutionary and Molecular Testing Laboratory at National Pingtung University of Science and Technology (NPUST), including 'Genetic Identification,' '8-Index Active Component Analysis,' and '16-Index Active Component Analysis.' We have also secured 'SGS Certification for Zero Western Medicine and Heavy Metal Contaminants.' Additionally, our China distributor has been awarded the 'Group Standard for Taiwanofungus Camphoratus Production Technical Specifications,' the sole certification of its kind issued by China's central authorities.
Inauguration of the Taiwanofungus Camphoratus Cultivation Base in Yilan, Taiwan
Our first dedicated Taiwanofungus Camphoratus cultivation base has been officially inaugurated in Yilan, Taiwan. This milestone marks the full-scale implementation of our cultivation initiative, with nearly 10,000 specialized cultivation units successfully deployed to date.
Appointment of Bao Quan Agri-Biotech (Shunde, Guangdong) as the Sole Agent in China
Bao Quan Agri-Biotech has been officially appointed with full authority to manage all sales, services, and related commercial activities for our patented porous ceramic carriers used in Taiwanofungus Camphoratus cultivation within the China market.
Becoming Taiwan's Largest Specialized Retail Chain for Antrodia Cinnamomea
We have established a premier retail presence with flagship stores in Taipei's historic Dihua Street, the vibrant Eastern District (Dongqu), and Kaohsiung's Sanfeng Zhong Street. Furthermore, we have expanded our reach by launching dedicated counters in Taipei's upscale department stores.
Successful Public Listing in the U.S. Market
C.S. Group has successfully completed its public filing with the U.S. Securities and Exchange Commission (SEC) and is now officially listed.
Official Establishment of the Antrodia Cinnamomea Breeding Center in Shunde, Guangdong
In partnership with our sole China agent, Bao Quan Agri-Biotech, we have established the first Taiwanofungus Camphoratus Breeding Center in Shunde, Guangdong. We are the first private enterprise to be officially designated as a 'Demonstration Base for Standardized TCM Agricultural Cultivation of Taiwanofungus Camphoratus by the Beijing Zhongnong Institute of Ecological Agriculture Science and Technology.
Launch of the JD.com Global Flagship Store
We have officially established our cross-border brand flagship store on JD.com. Through this platform, our premium range of Taiwanofungus Camphoratus health supplements is now available directly to consumers across mainland China via JD's sophisticated cross-border e-commerce network.
Expanding into the Veterinary Pharmaceutical Market
Successfully extracted Antcin A, the precious active compound from Taiwanofungus Camphoratus, to develop a novel non-steroidal anti-inflammatory drug (NSAID). Furthermore, we have formally initiated the application process for the 'New Multi-Compound Veterinary Drug Certificate' in Taiwan.